IceCure Medical (ICCM) is expecting to report a significant increase in Q4 sales in North America compared to the same period last year. Based on currently available preliminary information, the increase in sales would represent record North American sales levels for the Company. The Company is experiencing a surge of interest for the ProSense console and its disposable cryoprobes following the FDA’s marketing authorization of ProSense for the local treatment of low-risk breast cancer in women aged 70 and above in October. IceCure plans to report preliminary top-line revenue results in January 2026 followed by its full annual report on Form 20-F in April 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure’s ProSense® Cryoablation Gains Recognition at RSNA 2025
- IceCure Medical Secures Patent in China for Cryogen Flow Control
- IceCure Medical receives Notice of Patent Allowance from CNIPA
- IceCure Medical Announces Special General Meeting for Key Votes
- Promising Growth and Strategic Expansion Justify Buy Rating for Icecure Medical